Table 1.
Baseline Characteristics of BMC and Placebo Groupsa
| 3 Day | 7 Day | |||
|---|---|---|---|---|
| BMC N=43 |
Placebo N=24 |
BMC N=36 |
Placebo N=17 |
|
| Patient Characteristics: | ||||
| Age, mean (SD) | 55.6 (10.8) | 57.0 (12.4) | 58.2 (11.3) | 57.0 (8.0) |
| Female | 5 (11.6) | 3 (12.5) | 5 (13.9) | 2 (11.7) |
| Height in inches, mean (SD) | 69.7 (3.4) | 68.3 (3.1) | 68.9 (4.2) | 69.3 (4.5) |
| Weight in pounds, mean (SD) | 211.6 (41.4) | 197.6 (50.3) | 202.9 (45.1) | 214.7 (35.9) |
| BMI, mean (SD) | 30.5 (5.4) | 29.6 (6.8) | 29.9 (5.5) | 31.3 (3.3) |
| Race: | ||||
| White | 38 (88.4) | 20 (83.3) | 31 (86.1) | 15 (88.2) |
| Nonwhite | 5 (11.63) | 4 (16.67) | 5 (13.89) | 2 (11.76) |
| Qualifying LVEF % (echocardiogram), mean (SD) | 36.1 (6.1) | 37.8 (6.6) | 36.5 (6.3) | 36.6 (4.1) |
| History of: | ||||
| Diabetes | 10 (23.3) | 8 (33.3) | 4 (11.1) | 0 (0.0) |
| High Blood Pressure | 19 (44.2) | 15 (62.5) | 23 (63.9) | 13 (76.5) |
| Hyperlipidemia | 28 (65.1) | 15 (62.5) | 25 (69.4) | 13 (76.5) |
| Angina | 7 (16.3) | 2 (8.3) | 6 (16.7) | 5 (29.4) |
| Smoking | 28 (65.1) | 17 (70.8) | 19 (52.8) | 11 (64.7) |
| Initial Presentation at ED: | ||||
| Heart Rate | ||||
| Initial at ED, mean (SD) | 81.5 (14.2) | 78.7 (13.6) | 74.2 (15.3) | 82.3 (17.7) |
| median (range) | 82.0 (70.0-91.0) | 74.5 (70.0-90.5) | 75.5 (65.0-82.5) | 82.0 (75.0-89.0) |
| At discharge, mean (SD) (N=42 BMC 3 day) | 76.8 (12.1) | 79.5 (14.9) | 75.8 (10.4) | 78.1 (9.2) |
| median (range) | 74.5 (68.0-85.0) | 76.5 (70.0-88.5) | 77.5 (68.5-83.5) | 78.0 (72.0-82.0) |
| BP in mm Hg, mean (SD), (N=42 BMC 3 day) | ||||
| Systolic | 115.2 (14.0) | 115.4 (11.0) | 111.5 (16.4) | 112.0 (16.4) |
| Diastolic | 70.2 (10.7) | 68.3 (7.7) | 68.7 (11.2) | 69.5 (7.4) |
| Preinfarction Angina | 10 (23.3) | 7 (29.2) | 11 (30.6) | 7 (41.2) |
| Labs: | ||||
| Hemoglobin in gm/dL, mean (SD) (N=38 BMC 3 day, N=17 Placebo 3 day; N=29 BMC 7 day, N=15 Placebo 7 day) |
14.1 (1.7) | 12.8 (1.5) | 14.1 (1.5) | 13.9 (2.0) |
| hsCRP in mg/L, median (IQR) (N=39 BMC 3 day, N=21 Placebo 3 day; N=33 BMC 7 day, N=16 Placebo 7 day) |
20.8 (8.9-52.2) | 38.8 (10.8-49.4) | 28.1 (9.5-48.6)) | 34.0 (16.1-48.0) |
| BNP reg in pg/ml, median (IQR) (N=34 BMC 3 day, N=20 Placebo 3 day; N=30 BMC 7 day, N=15 Placebo 7 day) |
189.0 (90.0- 394.0) |
205.5 (118.0- 394.5) |
177.5 (139.0- 238.0) |
150.0 (125.0- 370.0) |
| Peak CKMB in ng/ml, median (IQR) (N=29 BMC 3 day, N=19 Placebo 3 day; N=31 BMC 7 day, N=15 Placebo 7 day) |
180.9 (42.1- 1302.0) |
133.0 (62.0- 432.7) |
402.0 (234.0- 466.0) |
227.0 (76.0- 442.0) |
| Peak Troponin in ng/ml, mean (SD) | ||||
| T (N=18 BMC 3 day, N=12 Placebo 3 day; N=21 BMC 7 day, N=14 Placebo 7 day) |
9.0 (7.8) | 6.2 (4.7) | 12.3 (8.1) | 10.9 (8.3) |
| I, mean (SD) (N=14 BMC 3 day, N=4 Placebo 3 day; N=5 BMC 7 day, N=1 Placebo 7 day) |
58.6 (82.6) | 46.1 (38.5) | 189.4 (140.6) | 128.9 (−) |
| MI Treatment: | ||||
| Ischemic Time in hours, median (IQR) | 3.4 (2.4-7.6) | 3.6 (2.2-8.6) | 4.0 (2.1-6.5) | 3.5 (2.2-11.8) |
| Door to Balloon in hours, median (IQR) (N=42 BMC 3 day) |
1.2 (0.7-1.7) | 1.3 (0.6-2.4) | 1.5 (1.0-1.9) | 1.2 (0.6-2.2) |
| Transferred from outside hosp. after PCI | 5 (11.6) | 2 (8.3) | 2 (5.6) | 0 (0) |
| Time from bone marrow aspiration to infusion in hours, median (IQR) |
8.4 (7.9-9.2) | 8.8 (8.0-9.5) | 7.9 (7.5-8.9) | 8.6 (7.8-9.0) |
| Time from PCI to infusion in days, median (IQR) (N=42 BMC 3 day) |
3.3 (2.8-3.8) | 3.2 (2.5-4.1) | 7.4 (7.0-7.9) | 7.6 (7.0-8.3) |
| Drug Eluting Stent | 33 (76.74) | 21 (87.50) | 29 (80.56) | 14 (82.35) |
| Stent Region: | ||||
| LAD | 37 (86.0) | 23 (95.8) | 35 (97.2) | 17 (100) |
| LAD only | 35 (81.4) | 22 (91.7) | 33 (91.7) | 17 (100) |
| LAD + LCX | 0 (0.0) | 1 (4.2) | 1 (2.8) | 0 (0.0) |
| LAD + RCA | 2 (4.7) | 0 (0.0) | 1 (2.8) | 0 (0.0) |
| LCX only | 1 (2.3) | 1 (4.7) | 1 (2.8) | 0 (0.0) |
| RCA only | 5 (11.6) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Medications at Time of Randomization: | ||||
| ACE inhibitor | 35 (81.4) | 19 (79.2) | 33 (91.7) | 13 (76.5) |
| Plavix/Plasugrel/Clopidogel | 42 (97.7) | 23 (95.8) | 33 (91.7) | 17 (100) |
| Aspirin | 42 (97.7) | 24 (100) | 34 (94.4) | 17 (100) |
| BetaBlockers | 42 (97.7) | 24 (100) | 35 (97.2) | 16 (94.1) |
| Statins | 39 (90.7) | 22 (91.7) | 34 (94.4) | 17 (100) |
| Diuretics | 7 (16.3) | 5 (20.8) | 11 (30.6) | 2 (11.8) |
| Coumadin/Warfarin/Lovenox | 4 (9.3) | 3 (12.5) | 11 (30.6) | 3 (17.7) |
Abbreviations: BMC, bone marrow mononuclear cell; BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); LVEF, left ventricular ejection fraction; ED, emergency department; hsCRP, highsensitivity C-reactive protein; BNP, brain natriuretic peptide; BP, blood pressure; IQR, interquartile range; PCI, percutaneous coronary intervention; LAD, left anterior descending coronary artery; LCX, left circumflex coronary artery; RCA, right coronary artery
a
Data are presented as No. (%) unless otherwise specified.